Saturday 17 October 2026 Export MXCT’s income statement to Excel — free account

MaxCyte, Inc.

MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.0 million, down 14.5% from fiscal 2024. In the quarter to June 2026, revenue fell 14.5%, EPS grew 33.3% and free cash flow grew 54.7%, each against the same quarter a year earlier.

1.30 0.00 0.00%

Follow MXCT

Alert me

Market cap: $134.2M
P/E: 0.0×
Fwd P/E: −6.1×
Dividend yield: —
F-score: 2/9
Altman Z: 1.32
Beneish M: −2.89
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	1	—	—	—	—	—	—	—

Insider Ownership 11.29%

Capital & Financial Ratios $m

Market Cap 134.17

Revenue 31.05

Net Income (35.64)

Free Cash Flow (23.64)

Net Debt (105.69)

Current Ratio 12.26

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (6.08)

P/S ratio 4.47

P/B ratio 0.87

Past 5Y EPS Growth —

This Y EPS Growth 34.78%

Next Y EPS Growth 6.91%

Next Y revenue growth 49.70%

Next 5Y EPS Growth 17.03%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 14.43%

10-year low 10-year high

P/B against its own 10 years 13.24%

10-year low 10-year high

EV/Sales against its own 10 years 10.12%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	168	154	103	106
Receivables	6	5	4	4
Inventory	12	9	8	8
Other	—	—	—	0
	190	172	118	121

	2023	2024	2025	Q'26
Payables	1	1	1	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	18	16	14	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	4.76%	(9.30%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	38.85%	(12.27%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	10	7	—	—	—
’25	10	9	7	7	33
’24	11	10	8	9	39
’23	9	9	8	16	41
’22	12	10	11	12	44
’21	6	7	10	10	34
’20	6	5	7	9	26

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(5)	—	—	—
’25	(14)	(10)	(7)	(3)	(34)
’24	(11)	(5)	(4)	(8)	(28)
’23	(4)	(10)	(8)	1	(22)
’22	(4)	1	(6)	(6)	(15)
’21	(5)	(4)	(1)	(1)	(11)
’20	(5)	(1)	(1)	(2)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(5)	—	—	—
’25	(15)	(10)	(8)	(3)	(36)
’24	(11)	(5)	(5)	(8)	(29)
’23	(6)	(11)	(9)	0	(25)
’22	(10)	(6)	(9)	(281)	(306)
’21	(5)	(5)	(2)	(267)	(279)
’20	(6)	(1)	(1)	(2)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.04)	(0.08)	—	—	—
’25	(0.10)	(0.12)	(0.12)	(0.09)	(0.42)
’24	(0.09)	(0.09)	(0.11)	(0.10)	(0.39)
’23	(0.11)	(0.10)	(0.11)	(0.05)	(0.37)
’22	(0.04)	(0.08)	(0.06)	(0.05)	(0.23)
’21	(0.09)	(0.05)	(0.03)	(0.05)	(0.21)
’20	(0.05)	(0.05)	(0.04)	(0.03)	(0.17)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	1.63	1.63	5.85	3.36	2.45	3.17	1.26	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	1.63	6.13	17.44	10.88	6.02	5.55	5.20
People
People	Employees	—	—	—	—	65	84	125	143	114	91
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.40	0.40	0.35	0.29	0.34	0.36
Income, $m
Income, $m	Revenue	11	19	21	22	26	34	44	41	39	33
	Gross margin, %	89.34	89.61	88.96	88.44	89.43	89.24	88.48	88.51	81.62	81.16
	EBT	(3)	(13)	(11)	(13)	(12)	(19)	(24)	(38)	(41)	(45)
	EBT margin, %	(27.27)	(70.91)	(53.21)	(59.64)	(45.15)	(56.30)	(53.25)	(91.85)	(106.29)	(135.14)
	Net income	(3)	0	(11)	(13)	(12)	(19)	(24)	(38)	(41)	(45)
	Depreciation	0	0	0	1	1	1	0	(3)	(2)	5
Per share, $
Per share, $	Revenue	0.34	0.39	0.42	0.38	0.38	0.37	0.44	0.40	0.37	0.31
	Earnings	(0.11)	(0.27)	(0.22)	(0.23)	(0.17)	(0.21)	(0.23)	(0.37)	(0.39)	(0.42)
	Cash flow	(0.06)	(0.27)	(0.26)	(0.16)	(0.13)	(0.12)	(0.15)	(0.21)	(0.26)	(0.32)
	Capex	0.00	0.00	0.00	(0.02)	(0.03)	(2.96)	(2.86)	(0.04)	(0.02)	(0.02)
	Free cash flow	(0.06)	(0.27)	(0.26)	(0.18)	(0.16)	(3.08)	(3.01)	(0.25)	(0.28)	(0.34)
	Book value	0.15	0.54	0.31	0.24	0.48	2.90	2.50	2.25	1.97	1.61
	Shares, m	34	49	51	56	69	91	102	103	105	106
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	0.00	16.27	27.24	11.76	12.51	11.29	5.00
	P/B	0.00	0.00	0.00	0.00	12.82	3.51	2.05	2.22	2.11	0.96
	EV/Sales	0.00	0.00	0.00	0.00	15.13	19.86	6.74	8.55	7.42	2.02
	EV/FCF	0.00	0.00	0.00	0.00	(36.48)	(2.41)	(0.98)	(13.91)	(9.79)	(1.85)
Cash, $m
Cash, $m	Operating cash flow	(2)	(13)	(13)	(9)	(9)	(11)	(15)	(22)	(28)	(34)
	Capex	0	(1)	(1)	(1)	(2)	(269)	(291)	(4)	(2)	(2)
	Free cash flow	(2)	(13)	(13)	(10)	(11)	(279)	(306)	(25)	(29)	(36)
Balance, $m
Balance, $m	Working capital	10	31	20	15	34	255	237	172	156	104
	Total debt	5	7	6	5	5	7	19	—	—	—
	Net debt	(7)	(27)	(12)	(12)	(30)	(255)	(227)	(168)	(154)	(103)
	Shareholders’ equity	5	26	16	14	33	263	254	232	206	171
Returns, %
Returns, %	ROA	(14.86)	(166.91)	(48.21)	(42.21)	(28.90)	(11.36)	(8.26)	(13.67)	(16.17)	(20.20)
	ROIC	0.00	0.00	0.00	(434.02)	(204.47)	(144.75)	(64.22)	(47.26)	(61.81)	(47.39)
	ROE	(28.58)	(84.92)	(53.85)	(87.88)	(50.47)	(12.89)	(9.12)	(15.60)	(18.73)	(23.63)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RXST RxSight, Inc.	$194.2M	— (loss-making)	— (loss-making)	+0.31% (above 0%: growing)	n/m	−94.39% (below 0%: shrinking)	76.72%	(40.81%)	Compare
INGN Inogen, Inc	$167.1M	— (loss-making)	— (loss-making)	+3.04% (above 0%: growing)	n/m	−51.15% (below 0%: shrinking)	45.51%	(5.36%)	Compare
STIM Neuronetics, Inc.	$148.6M	— (loss-making)	— (loss-making)	+9.08% (above 0%: growing)	n/m	+62.06% (above 0%: growing)	51.06%	(3.61%)	Compare
QTRX Quanterix Corporation	$145.2M	— (loss-making)	— (loss-making)	+34.44% (above 0%: growing)	n/m	+18.92% (above 0%: growing)	38.52%	(150.22%)	Compare
MXCT MaxCyte, Inc.	$134.2M	— (loss-making)	— (loss-making)	−14.53% (below 0%: shrinking)	n/m	+54.74% (above 0%: growing)	76.96%	(140.72%)
OWLT Owlet, Inc.	$129.8M	— (loss-making)	— (loss-making)	+29.94% (above 0%: growing)	n/m	+55.74% (above 0%: growing)	64.44%	5.14%	Compare
APYX Apyx Medical Corporation	$107.8M	— (loss-making)	— (loss-making)	+22.08% (above 0%: growing)	n/m	−137.38% (below 0%: shrinking)	63.89%	(13.01%)	Compare
LUCD Lucid Diagnostics Inc.	$105.7M	— (loss-making)	— (loss-making)	+26.74% (above 0%: growing)	n/m	−7.04% (below 0%: shrinking)	1.97%	(868.45%)	Compare
ZOMDF Zomedica Corp.	$95.4M	— (loss-making)	— (loss-making)	+36.59% (above 0%: growing)	n/m	+40.48% (above 0%: growing)	63.51%	(42.92%)	Compare
Median of peers	$137.5M	—	—	+24.41%	—	+5.94%	57.29%	(26.91%)

All 149 Medical Devices stocks →

MaxCyte, Inc. (MXCT) key facts

Concern: MaxCyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $33.0 million, down 14.5% from fiscal 2024.
Concern: MaxCyte, Inc. reported a net loss of $44.6 million, or a loss of $0.42 per share, for fiscal 2025.
MaxCyte, Inc. (MXCT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, MXCT traded at $1.30, a market capitalization of $134.2 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.5× sales.
Return on equity was −23.6% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 1.32 (distress zone) for fiscal 2025.